Company intelligence / Profile preview
TargEDys
Longjumeau, Île-de-France, Francebiocodex.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
TargEDys developed precision probiotic solutions targeting the gut-brain axis to regulate appetite and metabolic health. Its flagship product, EnteroSatys/Satylia, uses the Hafnia alvei HA4597 strain that produces ClpB—a protein mimicking human satiety hormones—to reduce hunger. The company was acquired by Biocodex in June 2023 after commercializing its lead products and securing patents related to obesity and metabolic disorders.
- Therapeutic areas
- EndocrinologyPsychiatryMetabolic Disorders
- Modalities
- Precision probioticslive biotherapeutic products
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on TargEDys.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TargEDys.